Indianapolis Firm Received $2.3 Million NCI Grant

Kovina Therapeutics secured federal funding to develop an oral therapy for HPV-related cancers.

Updated on Sept. 24, 2026 in Cancer

Indianapolis Firm Received $2.3 Million NCI Grant

Live Poll

Do you believe government funding for experimental cancer research programs provides good value for taxpayers?

The National Cancer Institute awarded a $2.3 million grant to Indianapolis-based Kovina Therapeutics. The funding supports two years of research to develop an oral small molecule therapy targeting HPV.

Why it matters

The grant enables essential studies required for an Investigational New Drug application, moving the company closer to clinical testing. This research aims to restore p53 tumor suppressor activity in patients battling HPV-driven cancers.

The grant funds studies over a two-year period to support IND-enabling development. This work addresses a significant health burden, as HPV causes approximately 39,300 cancers annually in the United States.

The players

Kovina Therapeutics

This Indianapolis-based biotechnology company focuses on developing small molecule therapeutics that target the HPV E6 oncoprotein.

National Cancer Institute

As a component of the National Institutes of Health, this agency conducts and supports research to advance cancer diagnosis and treatment.

The details

Kovina Therapeutics is developing a small molecule treatment designed to target the HPV E6 oncoprotein, which typically degrades the p53 tumor suppressor. This award, listed under number R44CA302154, covers the chemistry, manufacturing, and control processes, as well as necessary toxicology and pharmacology studies.

Kovina Therapeutics announced the grant award on September 24, 2026.
The NCI grant provides funding over a two-year duration.

Health Landscape

The National Cancer Institute's SBIR grant program provides critical capital to early-stage biotechnology firms, a mechanism that remains vital for translating academic oncology research into clinical applications. This award continues the broader trend of leveraging federal funding to address specific oncogenic drivers in challenging cancer types.

This development represents a long-term research effort that may eventually provide new treatment options for patients diagnosed with HPV-associated malignancies. The current phase focuses on regulatory-required studies rather than immediate clinical availability for the public.

The takeaway

Advancing small molecule drugs through the IND-enabling phase is a critical hurdle for any new cancer therapy. This federal investment highlights the importance of sustained financial support for specialized oncology programs before they reach human trials.